What question did this study set out to answer?

To compare the effectiveness of ustekinumab and JAK inhibitors against vedolizumab in ulcerative colitis after anti-TNF failure.

February 2, 2026Open Access

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

Key Points

To compare the effectiveness of ustekinumab and JAK inhibitors against vedolizumab in ulcerative colitis after anti-TNF failure.
Compared the efficacy of ustekinumab and JAK inhibitors to vedolizumab
Focused on steroid-free and biochemical remission rates
Considered safety profiles for patient selection
Ustekinumab and JAK inhibitors showed higher rates of steroid-free remission than vedolizumab
Biochemical remission rates were also significantly better with ustekinumab and JAK inhibitors
Safety concerns were noted for JAK inhibitors, highlighting the need for careful patient selection

Abstract

Ustekinumab and JAKi were more effective than vedolizumab in inducing steroid-free and biochemical remission following anti-TNFα failure. Safety concerns with JAKi warrant careful patient selection in clinical practice.

Ustekinumab and JAK inhibitors outperform vedolizumab as second-line therapy in anti-TNF-experienced patients with ulcerative colitis

Key Points

Abstract

Cite This Study

Also Consider

Also Consider